00:00 These drugs, the GLP-1 receptor agonists,
00:03 have shifted from being diabetes drugs to obesity drugs,
00:07 and now have the potential to modify important diseases
00:11 and add to our ability to treat heart disease
00:13 and other conditions as well.
00:15 So it is a landmark moment in the way we think
00:18 about GLP-1 receptor agonists and their role
00:21 in not only managing obesity,
00:24 but also managing patients' important conditions
Comments